{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:33:14Z","timestamp":1791124394330,"version":"4.1.0"},"reference-count":54,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T00:00:00Z","timestamp":1384732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>Bortezomib has demonstrated substantial activity in the treatment of patients with multiple myeloma and is widely incorporated into treatment strategies across the different settings. It is interesting to note that data are accumulating to suggest that the activity of bortezomib extends beyond the tumor cell and microenvironment to encompass effects on bone metabolism. Indeed, data from both the preclinical and clinical settings have suggested that bortezomib directly stimulates osteoblast growth and differentiation, while also inhibiting osteoclast development and activity. Notably, in the clinical setting, the bone anabolic effects of bortezomib could be demonstrated by the healing of lytic lesions as noted in some patients. These results are of importance because bone disease is a hallmark of myeloma and therefore any agent that combines antimyeloma activity with positive effects on bone is of substantial interest. However, further studies are needed to establish how the agent should be used for the treatment of patients with bone disease. <jats:bold><jats:italic>Cancer<\/jats:italic> 2014;120:618\u2013623<\/jats:bold>. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p>","DOI":"10.1002\/cncr.28481","type":"journal-article","created":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T22:10:10Z","timestamp":1384812610000},"page":"618-623","source":"Crossref","is-referenced-by-count":55,"title":["The effects of bortezomib on bone disease in patients with multiple myeloma"],"prefix":"10.1002","volume":"120","author":[{"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"Hematology Department Saint\u2010Antoine Hospital Paris France"},{"name":"INSERM (National Institute of Health and Medical Research) 938 Paris France"},{"name":"Pierre and Marie Curie University Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Malard","sequence":"additional","affiliation":[{"name":"INSERM (National Institute of Health and Medical Research) 938 Paris France"},{"name":"Hematology Department Nantes University Medical Center Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Mohty","sequence":"additional","affiliation":[{"name":"Transplantation and Cellular Therapy Unit Paoli\u2010Calmettes Institute Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplantation Section Division of Hematology\/Oncology Department of Medicine Vanderbilt University Medical Center and Veterans Affairs Medical Center Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"Hematology Department Nantes University Medical Center Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics University of Athens School of Medicine Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,18]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-036947"},{"key":"e_1_2_4_4_1","first-page":"59a","article-title":"Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial)","volume":"114","author":"Einsele H","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70187-X"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355081"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6180"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90034-X"},{"key":"e_1_2_4_13_1","first-page":"3071","article-title":"The proteasome inhibitor PS\u2010341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima T","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.202445099"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1999.0494"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.649"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000502"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90036-3"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M200360200"},{"key":"e_1_2_4_21_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.160.2.788","article-title":"Role of proteasomes in T cell activation and proliferation","volume":"160","author":"Wang X","year":"1998","journal-title":"J Immunol."},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.21006.x"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201519200"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204623"},{"key":"e_1_2_4_25_1","first-page":"1419","article-title":"Novel proteasome inhibitor PS\u2010341 inhibits activation of nuclear factor\u2010kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo JB","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi235"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.336"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0003"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16198"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.098"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404806"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.02.019"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21310"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.174"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.07.028"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059188"},{"key":"e_1_2_4_37_1","first-page":"491","article-title":"Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice","volume":"118","author":"Mukherjee S","year":"2008","journal-title":"J Clin Invest."},{"key":"e_1_2_4_38_1","first-page":"129","article-title":"Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation","volume":"33","author":"Munemasa S","year":"2008","journal-title":"Int J Oncol."},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.07.017"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06829.x"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174300"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01435.x"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.183"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05733.x"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00692.x"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06356.x"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.235"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.07030"},{"key":"e_1_2_4_49_1","first-page":"721a","article-title":"The addition of bortezomib to the combination of lenalidomide and dexamethasone increases bone formation in relapsed\/refractory myeloma: a prospective study in 91 patients","volume":"114","author":"Terpos E","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.n.045"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq259"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01485.x"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031302"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01599.x"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01523.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28481","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:09:30Z","timestamp":1760270970000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,18]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/cncr.28481"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28481","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,18]]}}}